What injectable medication(s) are recommended for an adult patient who requires additional LDL‑cholesterol lowering beyond diet, maximally tolerated statins, and ezetimibe?

Injectable Medications for Cholesterol Lowering

PCSK9 monoclonal antibodies (evolocumab or alirocumab) are the preferred injectable agents for adults requiring additional LDL-cholesterol reduction beyond maximally tolerated statins and ezetimibe, particularly in high and very-high cardiovascular risk patients. 1, 2

First-Line Injectable: PCSK9 Monoclonal Antibodies

Evolocumab and alirocumab should be prioritized as the initial injectable therapy because they have demonstrated cardiovascular outcomes benefits in large randomized trials (FOURIER and ODYSSEY Outcomes), with proven reductions in major adverse cardiovascular events and mortality. 1, 2

Key efficacy data:

• Reduce LDL-C by ≥50% when added to statin therapy 3
• Well-established safety and tolerability profile with minimal adverse events 3, 4
• Proven reduction in cardiovascular death, myocardial infarction, and stroke 1, 2

Risk-Stratified Thresholds for Injectable Therapy

Very High-Risk Patients (Secondary Prevention with ASCVD):

• Add PCSK9 inhibitor when LDL-C remains ≥100 mg/dL (≈2.6 mmol/L) despite maximally tolerated statin + ezetimibe 5, 2
• Class I, Level A recommendation for this population 5, 2
• Some guidelines support initiation at LDL-C ≥55 mg/dL for very-high risk patients 2

High-Risk Primary Prevention:

• Consider PCSK9 inhibitor when LDL-C remains elevated despite statin + ezetimibe 5
• Weaker recommendation (Class IIb, Level C) compared to secondary prevention 5, 2

Statin-Intolerant Patients:

• PCSK9 inhibitors approved for patients unable to tolerate statins with LDL-C ≥135 mg/dL (≈3.5 mmol/L) at very high cardiovascular risk 5
• Can be used as monotherapy or combined with ezetimibe 2

Alternative Injectable: Inclisiran

Inclisiran (siRNA-based PCSK9 inhibitor) is an alternative option for specific patient populations, but should not be first-line. 1, 2

When to consider inclisiran:

• Documented poor adherence to PCSK9 monoclonal antibodies 1, 2
• Patients unable to self-inject frequently 1, 2
• Advantage of twice-yearly dosing after loading phase (versus every 2-4 weeks for monoclonal antibodies) 1, 3

Critical limitation:

• Cardiovascular outcomes data not yet available—ORION-4 and VICTORION-2P trials anticipated completion 2026-2027 1
• Should be used in place of (not in addition to) PCSK9 monoclonal antibodies—no additive benefit demonstrated 1, 2

Stepwise Algorithm Before Injectable Therapy

Before initiating any injectable agent, confirm these prerequisites:

1. Maximize oral therapy first:

   • Highest tolerated statin dose achieved 1, 2
   • Ezetimibe added when LDL-C ≥70 mg/dL (≈1.8 mmol/L) on statin 5, 2
   • Ezetimibe provides additional ~20% LDL-C reduction with excellent safety 3

2. Verify adherence and lifestyle optimization:

   • Assess medication adherence before escalation 2
   • Confirm cholesterol-lowering diet and exercise program 1
   • Address any statin-associated side effects 1

3. Consider bempedoic acid before injectables:

   • Oral alternative providing ~17% additional LDL-C reduction 1
   • Useful for patients preferring to avoid injections 1
   • Use caution in patients with gout history or tendon rupture 1

Critical Pitfalls to Avoid

Do NOT use injectable therapy in:

• Low cardiovascular risk patients—burden outweighs modest benefit (strong recommendation against) 5, 2
• Patients not yet on maximally tolerated statin therapy 1, 2
• Patients who have not trialed ezetimibe first (unless specific contraindication) 1, 5, 2

Do NOT combine:

• PCSK9 monoclonal antibody + inclisiran together—no evidence of additive benefit 1, 2

Special monitoring considerations:

• Refer to lipid specialist if LDL-C remains <50% reduced or ≥70 mg/dL despite combination therapy with statin, ezetimibe, and PCSK9 inhibitor 1
• Patients with familial hypercholesterolemia may require additional therapies (evinacumab, lomitapide, LDL apheresis) under specialist care 1

Practical Implementation

Dosing schedules:

• Evolocumab: 140 mg subcutaneously every 2 weeks or 420 mg monthly 2
• Alirocumab: 75-150 mg subcutaneously every 2 weeks 2
• Inclisiran: 284 mg subcutaneously at baseline, 3 months, then every 6 months 1, 2

All injectable agents can be administered with or without food and do not require timing relative to other lipid medications. 2